Celltrion’s Global Ambitions On Track As Third Biosimilar Approved In US
Executive Summary
With the US approval of its third biosimilar product, Herzuma, Korean group Celltrion appears to be on a continued growth track in the global market, despite intensifying competition. The company is counting on Herzuma’s potential to rapidly replace Herceptin in the world’s biggest pharma market, given the higher price of the original drug.
You may also be interested in...
Celltrion Hit By Truxima Price Cut, Temporary Utilization Rate Drop
Intensifying competition in the global biosimilars space and a temporary drop in its factory utilization rate took a toll on Celltrion's earnings in the third quarter, but analysts still expect a rosy outlook next year amid the expected US launches of biosimilar rituximab and trastuzumab, and the first subcutaneous version of Remsima on the horizon in Europe.
Celltrion's Trastuzumab Biosimilar Gets EC Nod
With the latest EC approval, Celltrion's trastuzumab biosimilar Herzuma is set to compete with Samsung's Ontruzant, which received approval late last year.
No Korea-Originated New Drugs Approved Domestically In 2023
Notable new drug approvals in South Korea last year included Pfizer’s Tukysa, Genentech’s Columvi and BeiGene’s Tevimbra, but the tally did not include any domestically-originated products. Alzheimer’s disease therapy lecanemab may be on the horizon this year.